{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T03:54:34Z","timestamp":1787889274854,"version":"build-2784847793"},"reference-count":53,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002456","name":"Chonnam National University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002456","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.mayocp.2023.02.007","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:58:17Z","timestamp":1685062697000},"page":"1310-1322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Renin-Angiotensin-Aldosterone System Inhibitions and Cardiovascular Outcomes in Acute Myocardial Infarction With Renal Impairment"],"prefix":"10.1016","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6193-2982","authenticated-orcid":false,"given":"Seok","family":"Oh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3186-0770","authenticated-orcid":false,"given":"Ju Han","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0377-6352","authenticated-orcid":false,"given":"Kyung Hoon","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6026-1702","authenticated-orcid":false,"given":"Min Chul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4162-7902","authenticated-orcid":false,"given":"Doo Sun","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0192-8161","authenticated-orcid":false,"given":"Young Joon","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2022-9366","authenticated-orcid":false,"given":"Youngkeun","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2424-810X","authenticated-orcid":false,"given":"Myung Ho","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.mayocp.2023.02.007_bib1","first-page":"544","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"74","author":"Collet","year":"2021","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"12","key":"10.1016\/j.mayocp.2023.02.007_bib2","first-page":"1082","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"70","author":"Ibanez","year":"2017","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"22","key":"10.1016\/j.mayocp.2023.02.007_bib3","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/01.CIR.97.22.2202","article-title":"Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials","volume":"97","year":"1998","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.mayocp.2023.02.007_bib4","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","article-title":"Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction","volume":"333","author":"Kober","year":"1995","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.mayocp.2023.02.007_bib5","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"The SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N\u00a0Engl J Med"},{"issue":"9335","key":"10.1016\/j.mayocp.2023.02.007_bib6","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan","volume":"360","author":"Dickstein","year":"2002","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.mayocp.2023.02.007_bib7","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.mayocp.2023.02.007_bib8","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.mayocp.2023.02.007_bib9","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/ki.2010.550","article-title":"Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease: a collaborative meta-analysis of kidney disease population cohorts","volume":"79","author":"Astor","year":"2011","journal-title":"Kidney Int"},{"issue":"10","key":"10.1016\/j.mayocp.2023.02.007_bib10","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1161\/CIRCULATIONAHA.108.838169","volume":"120","author":"Szummer","year":"2009","journal-title":"Circulation"},{"issue":"9386","key":"10.1016\/j.mayocp.2023.02.007_bib11","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)","volume":"362","author":"Fox","year":"2003","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.mayocp.2023.02.007_bib12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.mayocp.2023.02.007_bib13","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.jacc.2016.01.050","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in myocardial infarction patients with renal dysfunction","volume":"67","author":"Evans","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.mayocp.2023.02.007_bib14","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1253\/circj.CJ-16-0061","article-title":"Multicenter Cohort Study of Acute Myocardial Infarction in Korea - Interim Analysis of the Korea Acute Myocardial Infarction Registry-National Institutes of Health Registry","volume":"80","author":"Kim","year":"2016","journal-title":"Circ J"},{"issue":"2","key":"10.1016\/j.mayocp.2023.02.007_bib15","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1053\/j.ajkd.2021.08.003","article-title":"A\u00a0unifying approach for GFR estimation: recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease","volume":"79","author":"Delgado","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.mayocp.2023.02.007_bib16","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1161\/01.CIR.82.4.1193","article-title":"Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease: implications for patient selection","volume":"82","author":"Ellis","year":"1990","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.mayocp.2023.02.007_bib17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0735-1097(97)00439-7","article-title":"Primary Angioplasty in Myocardial Infarction Stent Pilot Trial Investigators. Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: in-hospital and 30-day results of the PAMI stent pilot trial","volume":"31","author":"Stone","year":"1998","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.mayocp.2023.02.007_bib18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"issue":"6","key":"10.1016\/j.mayocp.2023.02.007_bib19","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/sim.6004","article-title":"A\u00a0comparison of 12 algorithms for matching on the propensity score","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"issue":"4","key":"10.1016\/j.mayocp.2023.02.007_bib20","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1037\/a0014268","article-title":"Average causal effects from nonrandomized studies: a practical guide and simulated example","volume":"13","author":"Schafer","year":"2008","journal-title":"Psychol Methods"},{"issue":"8suppl B","key":"10.1016\/j.mayocp.2023.02.007_bib21","first-page":"9","article-title":"The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition","volume":"13","author":"Atlas","year":"2007","journal-title":"J\u00a0Manag Care Pharm"},{"issue":"6","key":"10.1016\/j.mayocp.2023.02.007_bib22","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1161\/CIRCRESAHA.116.303587","article-title":"Hypertension: renin-angiotensin-aldosterone system alterations","volume":"116","author":"Te Riet","year":"2015","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.mayocp.2023.02.007_bib23","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.amjcard.2006.01.059","article-title":"Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease","volume":"98","author":"Ferrario","year":"2006","journal-title":"Am J Cardiol"},{"issue":"14","key":"10.1016\/j.mayocp.2023.02.007_bib24","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1161\/01.CIR.97.14.1411","article-title":"Angiotensin-converting enzyme inhibitors","volume":"97","author":"Brown","year":"1998","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.mayocp.2023.02.007_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1470320310370852","article-title":"Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects","volume":"12","author":"Miura","year":"2011","journal-title":"J\u00a0Renin Angiotensin Aldosterone Syst"},{"issue":"3","key":"10.1016\/j.mayocp.2023.02.007_bib26","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1161\/HYPERTENSIONAHA.110.167775","article-title":"Linking oxidative stress, the renin-angiotensin system, and hypertension","volume":"57","author":"Fanelli","year":"2011","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.mayocp.2023.02.007_bib27","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1046\/j.1523-1755.1998.00068.x","article-title":"Angiotensin II induces superoxide anion production by mesangial cells","volume":"54","author":"Jaimes","year":"1998","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.mayocp.2023.02.007_bib28","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1161\/01.HYP.0000144400.49062.6b","article-title":"Angiotensin II regulation of collagen type I expression in cardiac fibroblasts: modulation by PPAR-gamma ligand pioglitazone","volume":"44","author":"Chen","year":"2004","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.mayocp.2023.02.007_bib29","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/j.1476-5381.2010.00750.x","article-title":"Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status","volume":"160","author":"Ma","year":"2010","journal-title":"Br J Pharmacol"},{"issue":"9215","key":"10.1016\/j.mayocp.2023.02.007_bib30","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(00)02212-1","article-title":"ACE-Inhibitor Myocardial Infarction Collaborative Group. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients","volume":"355","author":"Flather","year":"2000","journal-title":"Lancet"},{"issue":"8746","key":"10.1016\/j.mayocp.2023.02.007_bib31","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/0140-6736(91)90202-Z","article-title":"Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition","volume":"337","author":"Sharpe","year":"1991","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.mayocp.2023.02.007_bib32","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/S0002-9149(99)80223-9","article-title":"Effect of early enalapril therapy on left ventricular function and structure in acute myocardial infarction","volume":"76","author":"Schulman","year":"1995","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.mayocp.2023.02.007_bib33","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s12872-017-0686-z","article-title":"Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials","volume":"17","author":"Tai","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"issue":"5","key":"10.1016\/j.mayocp.2023.02.007_bib34","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamainternmed.2014.348","article-title":"Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis","volume":"174","author":"Cheng","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"2","key":"10.1016\/j.mayocp.2023.02.007_bib35","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jacc.2012.10.011","article-title":"A\u00a0meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure","volume":"61","author":"Savarese","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"22","key":"10.1016\/j.mayocp.2023.02.007_bib36","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/CIRCULATIONAHA.117.026112","article-title":"Angiotensin receptor blockers do not reduce risk of myocardial infarction, cardiovascular death, or total mortality: further evidence for the ARB-MI paradox","volume":"135","author":"Strauss","year":"2017","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.mayocp.2023.02.007_bib37","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/HJH.0000000000000447","article-title":"Effects of blood pressure lowering on outcome incidence in hypertension: 4. effects of various classes of antihypertensive drugs\u2014overview and meta-analyses","volume":"33","author":"Thomopoulos","year":"2015","journal-title":"J\u00a0Hypertens"},{"issue":"16","key":"10.1016\/j.mayocp.2023.02.007_bib38","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1093\/eurheartj\/ehs075","article-title":"Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients","volume":"33","author":"van Vark","year":"2012","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.mayocp.2023.02.007_bib39","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1586\/erc.13.42","article-title":"The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review","volume":"11","author":"Ferrari","year":"2013","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"3","key":"10.1016\/j.mayocp.2023.02.007_bib40","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s40256-013-0058-8","article-title":"Differences in the clinical effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a critical review of the evidence","volume":"14","author":"Dezsi","year":"2014","journal-title":"Am J Cardiovasc Drugs"},{"issue":"4","key":"10.1016\/j.mayocp.2023.02.007_bib41","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cardiores.2003.11.037","article-title":"Review of aldosterone- and angiotensin II-induced target organ damage and prevention","volume":"61","author":"Struthers","year":"2004","journal-title":"Cardiovasc Res"},{"issue":"1pt 2","key":"10.1016\/j.mayocp.2023.02.007_bib42","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1161\/01.HYP.31.1.181","article-title":"Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis","volume":"31","author":"Border","year":"1998","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.mayocp.2023.02.007_bib43","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1161\/HYPERTENSIONAHA.114.03575","article-title":"Endothelial dysfunction and hypertension","volume":"64","author":"Brandes","year":"2014","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.mayocp.2023.02.007_bib44","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40119-019-00150-w","article-title":"A\u00a0review of the role of bradykinin and nitric oxide in the cardioprotective action of angiotensin-converting enzyme inhibitors: focus on perindopril","volume":"8","author":"Ancion","year":"2019","journal-title":"Cardiol Ther"},{"issue":"7","key":"10.1016\/j.mayocp.2023.02.007_bib45","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/emmm.201000080","article-title":"Angiotensin II revisited: new roles in inflammation, immunology and aging","volume":"2","author":"Benigni","year":"2010","journal-title":"EMBO Mol Med"},{"issue":"3","key":"10.1016\/j.mayocp.2023.02.007_bib46","first-page":"269","article-title":"RAAS inhibition and mortality in hypertension","volume":"2013","author":"Ferrari","year":"2013","journal-title":"Glob Cardiol Sci Pract"},{"issue":"1","key":"10.1016\/j.mayocp.2023.02.007_bib47","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.0000096609.73772.C5","article-title":"Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? implications for therapeutic blockade of the renin-angiotensin system","volume":"109","author":"L\u00e9vy","year":"2004","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.mayocp.2023.02.007_bib48","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1161\/ATVBAHA.109.195057","article-title":"Ablation of angiotensin IV receptor attenuates hypofibrinolysis via PAI-1 downregulation and reduces occlusive arterial thrombosis","volume":"29","author":"Numaguchi","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"10.1016\/j.mayocp.2023.02.007_bib49","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1161\/01.CIR.99.12.1593","article-title":"Pulmonary capillary endothelium-bound angiotensin-converting enzyme activity in humans","volume":"99","author":"Orfanos","year":"1999","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.mayocp.2023.02.007_bib50","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0022-3565(24)37201-5","article-title":"Differential distribution of angiotensin AT2 receptors in the normal and failing human heart","volume":"284","author":"Wharton","year":"1998","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"2pt 2","key":"10.1016\/j.mayocp.2023.02.007_bib51","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1161\/hy0202.103821","article-title":"Regulation of intrarenal angiotensin II in hypertension","volume":"39","author":"Navar","year":"2002","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.mayocp.2023.02.007_bib52","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12882-017-0605-7","article-title":"Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials","volume":"18","author":"Liu","year":"2017","journal-title":"BMC Nephrol"},{"issue":"18","key":"10.1016\/j.mayocp.2023.02.007_bib53","first-page":"e876","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: Executive Summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619623000642?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619623000642?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:40:28Z","timestamp":1758418828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619623000642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":53,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0025619623000642"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2023.02.007","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renin-Angiotensin-Aldosterone System Inhibitions and Cardiovascular Outcomes in Acute Myocardial Infarction With Renal Impairment","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2023.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc on behalf of Mayo Foundation for Medical Education and Research.","name":"copyright","label":"Copyright"}]}}